A study by Yale School of Medicine reveals that survival rates for patients with a thoracic aneurysm are significantly better, and complications are fewer, among patients who take statin cholesterol drugs than those who do not. The study appears in the American Journal of Cardiology.
- Administration - May 17
Getting to the bottom of how oceans breathe - Education - May 17
Faculty Senate explores the future of the doctoral degree - Microtechnics - May 17
Engineers’ new nanoscavenger purifies water, gets retrieved by magnet - Arts - May 17 Stanford adds two new freshman living, learning programs
- Medicine - May 17 Youth bullying because of perceived sexual orientation widespread and damaging
- Administration - May 17 Minnesota legislative conferees and Gov. Dayton support U of M requests to freeze tuition and invest in leading research
- Administration - May 17 Ingleside Post Office closes; alternate postal options available
- Pedagogy - May 17 New YaleNews website celebrates classroom teaching
- Life Sciences - May 17 Gene modification technology developed at University of Minnesota and Iowa State University receives patents
- Earth Sciences - May 17 U-M experts available to discuss Canadian earthquake felt in Michigan today
- Medicine - May 17 Playing doctor in the digital age
Statins may protect against death from aneurysm, Yale study finds
An aneurysm is a swelling of an artery, and is a common cause of death. It’s usually asymptomatic, with death or a life-threatening complication such as rupture or dissection being the first manifestation. Statins are cholesterol-lowering drugs that are widely used in patients with cardiovascular disease.
Assistant professor of cardiothoracic surgery Ion S. Jovin, M.D., and colleagues studied 649 patients with thoracic aortic aneurysms: 147 were taking statins and 502 were not. In long-term follow-up 80% of those taking statins survived, compared with 67% percent of those not taking statins. In addition, a smaller percentage of those taking statins suffered a rupture or dissection (splitting of the aorta), compared to those who were not taking statins.
"The intake of statins was associated with an improvement in long-term outcomes among these patients," said co-author John Elefteriades, M.D., professor of cardiothoracic surgery at Yale School of Medicine and director of the Aortic Institute at Yale-New Haven Hospital. "In addition to better survival, fewer patients taking statins required surgical intervention," Elefteriades added.
Medical science has searched for decades for a medicine that could treat aneurysm disease, with little success. The current standard therapy is to keep blood pressure low to discourage rupture of the enlarged artery. Jovin said his research suggests that "statins could offer a significant protective effect to patients at risk of death or complications from aneurysm disease. However, the ultimate proof would be a randomized clinical trial." Elefteriades adds, "We now have some arrows in our quiver of medicines to treat this disease."
Other authors are Mona Duggal, Keita Ebisu, Hyung Paek, A. Dana Oprea, Maryann Tranquilli, John Rizzo, Redin Memet, Marina Feldman, James Dziura, and Cynthia A. Brandt of Yale.
Last job offers
- Medicine - 18.5
Assistant Professor, Health Policy 1 - Medicine - 18.5
Assistant Professor, Health Policy 2 - Law - 18.5
Assistant or Associate Professor - Law - 18.5
Assistant or Associate Professor - Business - 18.5
Assistant Professor - Business - Medicine - 17.5
Neurology - Assistant, Associate, or Full Professor WOT (AA3458) - Medicine - 17.5
Medical Oncology - Assistant or Associate Professor WOT (AA3460) - Medicine - 17.5
Arlene Holden Chair in Breast Cancer Research






» Share this page: